A detailed history of Price T Rowe Associates Inc transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 16,078 shares of NAUT stock, worth $41,802. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,078
Previous 16,078 -0.0%
Holding current value
$41,802
Previous $48,000 20.83%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.41 - $3.18 $10,215 - $13,480
4,239 Added 35.81%
16,078 $48,000
Q4 2023

Feb 14, 2024

BUY
$2.34 - $3.39 $3,250 - $4,708
1,389 Added 13.29%
11,839 $36,000
Q3 2023

Nov 14, 2023

BUY
$2.87 - $3.94 $1,257 - $1,725
438 Added 4.37%
10,450 $34,000
Q2 2023

Aug 14, 2023

BUY
$2.21 - $4.52 $22,126 - $45,254
10,012 New
10,012 $39,000

Others Institutions Holding NAUT

About Nautilus Biotechnology, Inc.


  • Ticker NAUT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,663,000
  • Market Cap $324M
  • Description
  • Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...
More about NAUT
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.